Progyny (NASDAQ:PGNY) Sets New 52-Week Low – Here’s Why

Progyny, Inc. (NASDAQ:PGNY)’s share price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $16.60 and last traded at $16.65, with a volume of 143723 shares traded. The stock had previously closed at $16.97.

Analyst Ratings Changes

Several analysts have commented on PGNY shares. KeyCorp reduced their price objective on Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Canaccord Genuity Group decreased their price target on Progyny from $26.00 to $19.00 and set a “hold” rating for the company in a report on Wednesday, March 11th. JPMorgan Chase & Co. set a $35.00 price objective on shares of Progyny in a research report on Wednesday, January 21st. Citigroup raised shares of Progyny to an “outperform” rating in a report on Tuesday, January 20th. Finally, Zacks Research downgraded shares of Progyny from a “strong-buy” rating to a “hold” rating in a research report on Friday, January 30th. Nine analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $27.91.

Progyny Trading Up 0.1%

The firm has a 50 day moving average of $20.45 and a two-hundred day moving average of $22.32. The stock has a market capitalization of $1.39 billion, a PE ratio of 26.12, a P/E/G ratio of 1.00 and a beta of 1.01.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.48 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Progyny had a return on equity of 11.37% and a net margin of 4.54%.The business had revenue of $318.40 million during the quarter, compared to analysts’ expectations of $314.26 million. During the same quarter last year, the business posted $0.42 earnings per share. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.830-1.950 EPS and its Q1 2026 guidance at 0.420-0.450 EPS. Equities research analysts forecast that Progyny, Inc. will post 0.6 EPS for the current year.

Insider Buying and Selling at Progyny

In related news, EVP Allison Swartz sold 4,657 shares of Progyny stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $17.40, for a total transaction of $81,031.80. Following the completion of the transaction, the executive vice president directly owned 89,879 shares in the company, valued at $1,563,894.60. The trade was a 4.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 7,455 shares of company stock worth $129,515. Company insiders own 9.40% of the company’s stock.

Hedge Funds Weigh In On Progyny

Several hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in shares of Progyny by 2.4% in the third quarter. Vanguard Group Inc. now owns 10,106,147 shares of the company’s stock worth $217,484,000 after acquiring an additional 235,513 shares during the last quarter. State Street Corp raised its stake in Progyny by 1.5% in the 4th quarter. State Street Corp now owns 2,953,186 shares of the company’s stock valued at $75,838,000 after purchasing an additional 44,642 shares during the last quarter. Wellington Management Group LLP lifted its holdings in Progyny by 260.9% in the 4th quarter. Wellington Management Group LLP now owns 2,243,268 shares of the company’s stock valued at $57,607,000 after purchasing an additional 1,621,688 shares in the last quarter. Ameriprise Financial Inc. boosted its stake in shares of Progyny by 37.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 1,996,957 shares of the company’s stock worth $43,933,000 after purchasing an additional 545,431 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Progyny by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 1,972,219 shares of the company’s stock worth $50,655,000 after buying an additional 20,533 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.